NCT00207155View on ClinicalTrials.gov

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Cetuximab

IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.

Trial Locations (14)

Unknown

Local Institution, Duarte

Local Institution, Tampa

Local Institution, Baltimore

Local Institution, St Louis

Local Institution, New Brunswick

Local Institution, The Bronx

Local Institution, Cincinnati

Local Institution, Cleveland

Local Institution, Hershey

Local Institution, Philadelphia

Local Institution, Nashville

Local Institution, San Antonio

Local Institution, Montreal

Local Institution, Barcelona

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00207155 - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer | Biotech Hunter | Biotech Hunter